BioAlliance Pharma presents abstracts on Loramyc, clonidine Lauriad at MASCC/ISOO 2010 symposium

Jun 29 2010

BioAlliance Pharma SA (Paris:BIO), a company dedicated to the supportive care and treatment of cancer patients, has presented 2 abstracts on Loramyc^® and clonidine Lauriad^® at the MASCC/ISOO 2010 International Symposium (Vancouver, June 24-26, 2010). These two products belong to the supportive care pipeline of BioAlliance Pharma.

The 1^st abstract: « Effect of Salivary Flow on Efficacy of Miconazole Buccal Tablet (MBT) for Treatment of oropharyngeal candidiasis (OPC) » presented the results of the post-hoc analysis of a European phase III trial with Loramyc^® (miconazole Lauriad^®), mucoadhesive buccal tablet.

Reduced salivary flow resulting from radiotherapy treatment for head and neck cancer markedly affects the efficacy of treatments of OPC. The objective of this post-hoc analysis was to evaluate the efficacy of miconazole Lauriad^® 50mg once daily or miconazole oral gel 500mg four times daily in these patients with reduced salivary flow. It showed that miconazole Lauriad^® was an effective topical treatment for OPC in patients with reduced salivary flow with the major convenience of once-daily dosing.

BioAlliance Pharma's commercial partners for Loramyc^® are Therabel in Europe and Strativa Pharmaceuticals (the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies Inc.) in the United States.

The ongoing phase II trial with clonidine Lauriad^® was also presented: « A phase II, multicentre, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of Clonidine Lauriad^® 50 μg and 100 μg mucoadhesive buccal tablet (MBT) applied once daily in the prevention and treatment of chemoradiotherapy-induced oral mucositis in patients with head and neck cancer ».

Clonidine Lauriad^® uses the innovative muco-adhesive technology validated with Loramyc^® and more recently with acyclovir Lauriad^®. This new product is dedicated to the prevention and the treatment of radiotherapy and chemotherapy-induced oral mucositis in cancer patients.

SOURCE BioAlliance Pharma